All In Biotech

Drug Trial Radar · NCT00052936

Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma

Last checked: Nov 20, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,506 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,506

Actual

Start

Jan 2001

Primary completion

Aug 5, 2010

Study completion Aug 5, 2010

Sponsor

Lead sponsor
German High-Grade Non-Hodgkin's Lymphoma Study GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 61 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without rituximab in treating aggressive non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying how well giving cyclophosphamide, doxorubicin, vincristine, and prednisone together with or without rituximab works in treating older patients who have aggressive non-Hodgkin's lymphoma. (This trial is no longer randomized as of 6/2005).

Conditions

  • Lymphoma

Interventions

  • filgrastimBiological

  • rituximabBiological

  • CHOP regimenDrug

  • cyclophosphamideDrug

  • doxorubicin hydrochlorideDrug

  • prednisoneDrug

  • vincristine sulfateDrug

  • radiation therapyRadiation

    36Gy on BULK and extranodal involvement

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to treatment failure at 3 years within the study and then periodically after study completionTime frame: 3 years within the study and then periodically after study completion

Locations

174 sites in 2 countries. Site status is shown where the registry gives one.

  • Haematologisch Onkologische Praxis

    Aachen, Germany

  • Klinikum St. Marien

    Amberg, Germany

  • Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie

    Ansbach, Germany

  • II. Medizinische Klinik

    Aschaffenburg, Germany

  • Specialist Practice for Oncology

    Aschaffenburg, Germany

  • Haematologische Praxis

    Augsburg, Germany

  • Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg

    Augsburg, Germany

  • Klinikum Augsburg

    Augsburg, Germany

  • Kreiskrankenhaus Aurich

    Aurich, Germany

  • Regional Hospital Bad Hersfeld

    Bad Hersfeld, Germany

  • Humaine - Clinic

    Bad Saarow, Germany

  • Krankenhaus Hohe Warte Mediziniche Klinik

    Bayreuth, Germany

  • Robert Roessle Comprehensive Cancer Center - Charite Campus Buch

    Berlin, Germany

  • Haematologisch-Onkologische Schwerpunktpraxis

    Berlin, Germany

  • Hospital Complex Bernburg

    Bernburg, Germany

  • Krankenhaus Bietigheim

    Bietigheim, Germany

  • Saint Agnes Hospital

    Bocholt, Germany

  • Saint Josef Hospital

    Bochum, Germany

  • Knappschaft Krankenhaus

    Bochum, Germany

  • Medizinische Poliklinik

    Bonn, Germany

  • Rheinische Friedrich-Wilhelms-Universitat

    Bonn, Germany

  • DIAKO Ev. Diakonie Krankenhaus gGmbH

    Bremen, Germany

  • Medizinische Klinik Am Lukas - Krankenhaus

    Bünde, Germany

  • General Hospital

    Celle, Germany

  • Hospital Kuchwald Chemnitz

    Chemnitz, Germany

  • Praxis Fuer Haematologie Internistische Onkologie

    Cologne, Germany

  • Medizinische Universitaetsklinik I at the University of Cologne

    Cologne, Germany

  • Site not named

    Cologne-Kalk, Germany

  • Lung Clinic Cologne-Merheim

    Cologne-Merheim, Germany

  • Carl - Thiem - Klinkum Cottbus

    Cottbus, Germany

  • Klinikum Darmstadt

    Darmstadt, Germany

  • Saint Johannes Hospital Dortmund

    Dortmund, Germany

  • Universitatsklinikum Carl Gustav Carus

    Dresden, Germany

  • St. Johannes Hospital - Medical Klinik II

    Duisburg, Germany

  • Franz Hospital Dulmen

    Dülmen, Germany

  • Florence-Nightingale-Krankenhause, Deaconess Kaiserswerth

    Düsseldorf, Germany

  • Hans - Susemihl - Krankenhaus

    Emden, Germany

  • Klinikum Erfurt

    Erfurt, Germany

  • St. Antonius Hospital

    Eschweiler, Germany

  • Universitaetsklinikum Essen

    Essen, Germany

Showing 40 of 174 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.